Can CLVS Find Stability If Not Former Highs?

Clovis Oncology CLVS – NASDAQ

Thursday, May 11, 2017

If you think biotech stocks aren’t a risky proposition, take a look at Clovis Oncology CLVS – NASDAQ. In the first few months of the year, CLVS gained 67%. But over the last two months, it’s given back nearly all of it.

Can it reverse back higher? Whoever picked up 2,000 CLVS July 55/70 bull call spreads earlier today thinks so.


At $4.25 per spread, this trade cost $850,000. To pay off, CLVS needs to increase 29% to the break-even price of $59.25 by expiration.

This trade will achieve its maximum value at the short strike at $70 (+54%), wherein the returns top $2.15 million. Watch for pending results from a drug trial likely coming in July to be the necessary catalyst.

CEO Buys $1 Million of Own Stock: “I believe in putting my money where my mouth is,” he said after making such a public splash. And to back it up, he just delivered the best Q1 in company history. Click here to get the stock.

Sign up for free research.

Enter your email to receive
Free Research